US Stock MarketDetailed Quotes
GERN Geron
- 4.500
- +0.040+0.90%
Close Aug 16 16:00 ET
- 4.500
- 0.0000.00%
Post 20:02 ET
2.71BMarket Cap-12857P/E (TTM)
4.560High4.430Low6.52MVolume4.460Open4.460Pre Close29.36MTurnover1.17%Turnover RatioLossP/E (Static)602.80MShares5.34052wk High8.84P/B2.50BFloat Cap1.64052wk Low--Dividend TTM555.88MShs Float75.875Historical High--Div YieldTTM2.92%Amplitude0.750Historical Low4.504Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Geron Stock Forum
折扣价赶快买！
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron (GERN.US)$
https://stockregion.app/p/investment-bank-initiates-overweight
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline (GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
No comment yet